Previous Article | Next Article ![]()
Journal of Virology, October 2007, p. 10362-10378, Vol. 81, No. 19
0022-538X/07/$08.00+0 doi:10.1128/JVI.00703-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
B-Box 2 Domain
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Department of Pathology, Division of AIDS, Harvard Medical School, Boston, Massachusetts 02115,1 Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts 021152
Received 3 April 2007/ Accepted 2 July 2007
An intact B-box 2 domain is essential for the antiretroviral activity of TRIM5
. We modeled the structure of the B-box 2 domain of TRIM5
based on the existing three-dimensional structure of the B-box 2 domain of human TRIM29. Using this model, we altered the residues predicted to be exposed on the surface of this globular structure. Most of the alanine substitutions in these residues exerted little effect on the antiretroviral activity of human TRIM5
hu or rhesus monkey TRIM5
rh. However, alteration of arginine 119 of TRIM5
hu or the corresponding arginine 121 of TRIM5
rh diminished the abilities of the proteins to restrict retroviral infection without affecting trimerization or recognition of the viral capsid. The abilities of these functionally defective TRIM5
proteins to accelerate the uncoating of the targeted retroviral capsid were abolished. Removal of the positively charged side chain from B-box 2 arginines 119/120/121 resulted in diminished proteasome-independent turnover of TRIM5
and the related restriction factor TRIMCyp. However, testing of an array of mutants revealed that the rapid turnover and retroviral restriction functions of this B-box 2 region are separable.
Published ahead of print on 11 July 2007.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»